KD025 (SLx-2119) is primarily used in the field of medical research and therapeutics, particularly as a selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). Its application is significant in the study and treatment of various diseases, including autoimmune disorders, fibrotic diseases, and certain types of cancer. By targeting ROCK2, it modulates immune responses and reduces inflammation, making it a potential candidate for conditions like psoriasis, rheumatoid arthritis, and chronic graft-versus-host disease. Additionally, its antifibrotic properties are being explored for treating liver fibrosis and idiopathic pulmonary fibrosis. In oncology, KD025 is investigated for its role in inhibiting tumor growth and metastasis by affecting signaling pathways involved in cancer progression. Its therapeutic potential continues to be evaluated in clinical trials, aiming to provide new treatment options for these complex diseases.